PTC Therapeutics (PTCT) acquired ST-920, a Fabry disease gene therapy from Sangamo Therapeutics (SGMOQ), through a court-supervised auction. The deal includes an upfront cash payment of $111 million, with potential for an additional $80 million upon FDA accelerated approval and $20 million upon traditional approval, totaling up to $211 million. This surpassed a stalking horse bid from Astellas Pharma (TSE: 4503), and is structured as an asset purchase with regulatory milestone payments rather than an equity investment or royalty arrangement. PTC has secured a late-stage clinical asset, bypassing early-stage research risks and reducing the launch gap in its rare disease portfolio.

ST-920 is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver the GLA gene to the liver, enabling sustained production of alpha-galactosidase A. The STAAR Phase 1/2 open-label, multi-center study enrolled 33 adult patients, with 32 patients having 52-week data. The mean annualized eGFR slope was 1.965 mL/min/1.73m²/year, with a 95% confidence interval of -0.153 to 4.083. In an October 2024 Type B meeting, the FDA accepted the 52-week eGFR slope as a primary endpoint for accelerated approval and requested 104-week data to confirm clinical benefit. A rolling BLA submission is underway, with PTC planning to complete the submission by the fourth quarter of 2026 and aiming for a 2027 launch.

The Fabry disease market is projected to grow from approximately $2.2 billion in 2025 to $3.2 billion in 2031, with enzyme replacement therapy (ERT) accounting for 67.85% of sales in 2025. Current standard treatments include Fabrazyme and Agalsidase Beta from Sanofi (SNY), Replagal and Agalsidase Alfa from Takeda (TAK), and Elfabrio and Pegunigalsidase Alfa from Chiesi and Protalix (PLX), all requiring repeated intravenous infusions. Amicus's Galafold and Migalastat, an oral chaperone that stabilizes a mutant alpha-galactosidase A, generated $521.7 million in sales in 2025 but is limited to patients with specific GLA mutations. ST-920, a single-dose candidate, needs to demonstrate sustained enzyme expression and the potential to discontinue ERT to disrupt this repeat-revenue market.

The $111 million upfront payment represents a capital-efficient entry price for PTC, considering the development timeline and prior investment in a BLA-stage rare disease asset. However, accelerated approval is not guaranteed, and the 52-week eGFR confidence interval includes zero. The FDA review will consider the overall clinical data, as well as safety, durability, and manufacturing quality. The approval and potential for full approval will depend on the completion of the BLA in 2026, the FDA's review timeline, and the readiness for a 2027 launch. The co-development of a companion diagnostic for AAV6 neutralizing antibody screening, the CMC module, long-term follow-up, and the 104-week validation data are also critical for approval and full approval.